Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein
This article was originally published in The Rose Sheet
Executive Summary
In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process clearer to the public (1"The Rose Sheet" June 15, 2009). The task force held two public meetings and accepted comments through Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings, with draft recommendations expected by January.
You may also be interested in...
FDA Unveils Plan To Boost Transparency To Industry
FDA has identified 19 steps to improve its communications with drug and medical device manufacturers, promising quicker responses to industry questions.
FDA Unveils Plan To Boost Transparency To Industry
FDA has identified 19 steps to improve its communications with drug and medical device manufacturers, promising quicker responses to industry questions.
FDA Task Force Created To Promote Transparency, Solicit Public Input
FDA's formation of an internal Transparency Task Force is a savvy move that allows agency leaders to begin making good on their pledge to enhance openness while having six months before them to decide how exactly that will be done